Paul McNally

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele

Edith T. Zemanick, Jennifer L. Taylor‐Cousar, Jane C. Davies et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 261 citations · Full text

The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic Fibrosis Airway

Bojana Mirković, Michelle Murray, Gillian Lavelle et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 135 citations · Full text

LL-37 Complexation with Glycosaminoglycans in Cystic Fibrosis Lungs Inhibits Antimicrobial Activity, Which Can Be Restored by Hypertonic Saline

Gudmundur Bergsson, Emer P. Reeves, Paul McNally et al. · The Journal of Immunology · 2009 · 129 citations

Decreased Levels of Secretory Leucoprotease Inhibitor in the <i>Pseudomonas</i> -Infected Cystic Fibrosis Lung Are Due to Neutrophil Elastase Degradation

Sinéad Weldon, Paul McNally, Noel G. McElvaney et al. · The Journal of Immunology · 2009 · 119 citations · Full text

Elafin, an Elastase-specific Inhibitor, Is Cleaved by Its Cognate Enzyme Neutrophil Elastase in Sputum from Individuals with Cystic Fibrosis

Nicolas Guyot, Marcus W. Butler, Paul McNally et al. · Journal of Biological Chemistry · 2008 · 94 citations · Full text

Inflammation, Protease Inhibitors, Elastase-specific Inhibitor +14